In the last trading session, 1.86 million ARS Pharmaceuticals Inc (NASDAQ:SPRY) shares changed hands as the company’s beta touched 0.89. With the company’s per share price at $16.09 changed hands at -$1.36 or -7.79% during last session, the market valuation stood at $1.58B. SPRY’s last price was a discount, traded about -17.46% off its 52-week high of $18.90. The share price had its 52-week low at $8.35, which suggests the last value was 48.1% up since then. When we look at ARS Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.05 million shares, with the 3-month average coming to 1.56 million.
Analysts gave the ARS Pharmaceuticals Inc (SPRY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SPRY as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Instantly SPRY was in red as seen at the end of in last trading. With action -4.11%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 99.88%, with the 5-day performance at -4.11% in the red. However, in the 30-day time frame, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is 11.50% up. Looking at the short shares, we see there were 16.58 million shares sold at short interest cover period of 12.13 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 26.86% from its current market value. According to analyst projections, SPRY’s forecast low is 18 with 30 as the target high. To hit the forecast high, the stock’s price needs a -86.45% plunge from its current level, while the stock would need to soar -11.87% for it to hit the projected low.
The 2025 estimates are for ARS Pharmaceuticals Inc earnings to decrease by -1891.25%, but the outlook for the next 5-year period is at 58.89% per year.
SPRY Dividends
ARS Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-14.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 16.93% of ARS Pharmaceuticals Inc shares while 80.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 96.65%. There are 80.28% institutions holding the ARS Pharmaceuticals Inc stock share, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) the top institutional holder. As of 2024-06-30, the company held 11.4409% of the shares, roughly 11.08 million SPRY shares worth $94.27 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 11.2168% or 10.86 million shares worth $92.43 million as of 2024-06-30.
